PF-07321332, an antiviral drug being developed by Pfizer, is designed to attack the “spine” of the COVID-19 virus to prevent it from replicating in the nose, throat, and lungs, according to the Telegraph.
Trials involving volunteers from age 18 to 60 are now underway at Pfizer facilities in both the United States and Europe, according to the report.
Pizer's director of medicinal chemistry, Dafydd Owen, said the pill was developed from scratch, the Telegraph said.
Click here to follow Daily Voice Beekman-Poughquag and receive free news updates.